Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Sep;38(9):2210–2212. doi: 10.1128/aac.38.9.2210

Penetration of cefprozil into middle ear fluid of patients with otitis media.

W C Shyu 1, J Haddad 1, J Reilly 1, W N Khan 1, D A Campbell 1, Y Tsai 1, R H Barbhaiya 1
PMCID: PMC284715  PMID: 7811050

Abstract

Penetration of cefprozil into the middle ear fluid was investigated in patients with chronic otitis media. A total of 89 patients ranging from 7 months to 11 years old participated in the study. The middle ear fluid was removed by ventilation tubes inserted through the tympanic membrane at times ranging from 0.38 to 5.97 h after oral administration of a single dose of 15 or 20 mg/kg of body weight. A blood sample was also collected as soon as the middle ear fluid was removed. Plasma samples were analyzed for the concentration of cefprozil by a high-performance liquid chromatographic assay. Middle ear fluid samples were analyzed for the concentration of cefprozil by a microbiological assay. The concentrations of cefprozil in plasma ranged from 0.38 to 15.97 micrograms/ml at the 15-mg/kg dose level and from 1.28 to 21.47 micrograms/ml at the 20-mg/kg dose level. The corresponding middle ear fluid concentrations of cefprozil ranged from 0.06 to 4.44 micrograms/ml and from 0.17 to 8.67 micrograms/ml, respectively. Cefprozil penetrates well into middle ear fluid in patients with chronic otitis media.

Full text

PDF
2210

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bowie W. R., Shaw C. E., Chan D. G., Black W. A. In vitro activity of Ro 15-8074, Ro 19-5247, A-56268, and roxithromycin (RU 28965) against Neisseria gonorrhoeae and Chlamydia trachomatis. Antimicrob Agents Chemother. 1987 Mar;31(3):470–472. doi: 10.1128/aac.31.3.470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Chin N. X., Neu H. C. Comparative antibacterial activity of a new oral cephalosporin, BMY-28100. Antimicrob Agents Chemother. 1987 Mar;31(3):480–483. doi: 10.1128/aac.31.3.480. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Eliopoulos G. M., Reiszner E., Wennersten C., Moellering R. C., Jr In vitro activity of BMY-28100, a new oral cephalosporin. Antimicrob Agents Chemother. 1987 Apr;31(4):653–656. doi: 10.1128/aac.31.4.653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Haddad J., Jr, Isaacson G., Respler D. S., Hart R. W., Yilmaz H. M., Collins J. J., Bluestone C. D. Concentration of cefuroxime in serum and middle ear effusion after single dose treatment with cefuroxime axetil. Pediatr Infect Dis J. 1991 Apr;10(4):294–298. doi: 10.1097/00006454-199104000-00006. [DOI] [PubMed] [Google Scholar]
  5. Kirst H. A., Sides G. D. New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy. Antimicrob Agents Chemother. 1989 Sep;33(9):1419–1422. doi: 10.1128/aac.33.9.1419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kirst H. A., Sides G. D. New directions for macrolide antibiotics: structural modifications and in vitro activity. Antimicrob Agents Chemother. 1989 Sep;33(9):1413–1418. doi: 10.1128/aac.33.9.1413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Krause P. J., Owens N. J., Nightingale C. H., Klimek J. J., Lehmann W. B., Quintiliani R. Penetration of amoxicillin, cefaclor, erythromycin-sulfisoxazole, and trimethoprim-sulfamethoxazole into the middle ear fluid of patients with chronic serous otitis media. J Infect Dis. 1982 Jun;145(6):815–821. doi: 10.1093/infdis/145.6.815. [DOI] [PubMed] [Google Scholar]
  8. Leitner F., Pursiano T. A., Buck R. E., Tsai Y. H., Chisholm D. R., Misiek M., Desiderio J. V., Kessler R. E. BMY 28100, a new oral cephalosporin. Antimicrob Agents Chemother. 1987 Feb;31(2):238–243. doi: 10.1128/aac.31.2.238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Martini A., Xerri L. Study of diffusion of cefuroxime into middle ear effusions of patients with chronic purulent otitis media. J Antimicrob Chemother. 1982 Sep;10(3):197–198. doi: 10.1093/jac/10.3.197. [DOI] [PubMed] [Google Scholar]
  10. Nelson J. D., Ginsburg C. M., Mcleland O., Clahsen J., Culbertson M. C., Jr, Carder H. Concentrations of antimicrobial agents in middle ear fluid, saliva and tears. Int J Pediatr Otorhinolaryngol. 1981 Dec;3(4):327–334. doi: 10.1016/0165-5876(81)90057-4. [DOI] [PubMed] [Google Scholar]
  11. Robson H. G., Shah P. P., Lalonde R. G., Hayes L., Senikas V. M. Comparison of rosaramicin and erythromycin stearate for treatment of cervical infection with Chlamydia trachomatis. Sex Transm Dis. 1983 Jul-Sep;10(3):130–134. doi: 10.1097/00007435-198307000-00006. [DOI] [PubMed] [Google Scholar]
  12. Scieux C., Bianchi A., Chappey B., Vassias I., Pérol Y. In-vitro activity of azithromycin against Chlamydia trachomatis. J Antimicrob Chemother. 1990 Jan;25 (Suppl A):7–10. doi: 10.1093/jac/25.suppl_a.7. [DOI] [PubMed] [Google Scholar]
  13. Scribner R. K., Marks M. I., Finkhouse B. D. In vitro activity of BMY-28100 against common isolates from pediatric infections. Antimicrob Agents Chemother. 1987 Apr;31(4):630–631. doi: 10.1128/aac.31.4.630. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Segreti J., Kessler H. A., Kapell K. S., Trenholme G. M. In vitro activity of A-56268 (TE-031) and four other antimicrobial agents against Chlamydia trachomatis. Antimicrob Agents Chemother. 1987 Jan;31(1):100–101. doi: 10.1128/aac.31.1.100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Stutman H. R., Arguedas A. G. Comparison of cefprozil with other antibiotic regimens in the treatment of children with acute otitis media. Clin Infect Dis. 1992 Jun;14 (Suppl 2):S204–S211. doi: 10.1093/clinids/14.supplement_2.s204. [DOI] [PubMed] [Google Scholar]
  16. Walsh M., Kappus E. W., Quinn T. C. In vitro evaluation of CP-62,993, erythromycin, clindamycin, and tetracycline against Chlamydia trachomatis. Antimicrob Agents Chemother. 1987 May;31(5):811–812. doi: 10.1128/aac.31.5.811. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Washington A. E., Johnson R. E., Sanders L. L., Jr Chlamydia trachomatis infections in the United States. What are they costing us? JAMA. 1987 Apr 17;257(15):2070–2072. [PubMed] [Google Scholar]
  18. Yu K. W., Neu H. C. In vitro activity of dirithromycin (LY 237216) compared with activities of other macrolide antibiotics. Antimicrob Agents Chemother. 1990 Sep;34(9):1839–1842. doi: 10.1128/aac.34.9.1839. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES